Form 4: Dyne Therapeutics CFO Erick Lucera Reports Stock and Option Awards

Chief Financial Officer Erick Lucera reports the acquisition of restricted stock units and stock options in Dyne Therapeutics.

Summary

• Erick Lucera, CFO of Dyne Therapeutics, filed a Form 4 on April 1, 2025, reporting transactions from March 31, 2025.
• Lucera acquired 66,100 shares of Common Stock through restricted stock units (RSUs) at a price of $0.
• These RSUs vest in equal annual installments over four years, starting March 31, 2026, contingent upon continuous service.
• Lucera also acquired options to purchase 214,500 shares of Common Stock at an exercise price of $10.46.
• These options vest over four years, with 25% vesting on March 31, 2026, and the remainder in 12 equal quarterly installments thereafter, subject to continuous service.
• Following these transactions, Lucera directly owns 66,100 shares of Common Stock and options for 214,500 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing reflects standard compensation practices, aligning management interests with shareholders through equity ownership. There are no red flags or negative indicators.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedules incentivize long-term commitment and performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders can monitor insider transactions to assess management's confidence in the company.
• Employees may be impacted by the vesting schedules, which incentivize long-term commitment.

Key Dates

Keywords

Form 4, Dyne Therapeutics, DYN, Erick Lucera, CFO, restricted stock units, stock options, beneficial ownership, insider trading